Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
Portfolio Pulse from Vandana Singh
Novartis AG (NVS) released data from the ALITHIOS study showing sustained efficacy of Kesimpta in treating relapsing multiple sclerosis for up to six years. The study highlighted significant benefits over Sanofi SA's (SNY) Aubagio, including fewer relapses and MRI lesions, and less disability worsening. Kesimpta's sales nearly doubled to $2.2 billion in fiscal year 2023. NVS shares saw a slight increase of 0.15% to $93.34.
April 17, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis AG's Kesimpta demonstrates long-term efficacy in treating relapsing multiple sclerosis, with sales nearly doubling to $2.2 billion in fiscal year 2023. NVS shares increased slightly by 0.15%.
The positive data from the ALITHIOS study and the significant increase in Kesimpta's sales are likely to have a positive short-term impact on NVS's stock price. The reported efficacy of Kesimpta and its financial performance are directly relevant to Novartis' market valuation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Sanofi SA's Aubagio was outperformed by Novartis' Kesimpta in treating relapsing multiple sclerosis, according to the ALITHIOS study.
The direct comparison in the ALITHIOS study showing Kesimpta's superior efficacy over Aubagio could potentially have a negative short-term impact on SNY's stock price, as it may affect Aubagio's market perception and sales.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80